IXICO PLC's (LON:IXI) CEO Giulio Cerroni joins Proactive London's Katie Pilbeam to discuss what was driving their strong first half performance. Revenues increased 8% and its order book rose to £19mln in the past six months despite the disruption caused by Coronavirus (COVID-19).
Cerroni also explains the details behind the announcement issued on 23 March 2021, that IXICO’s largest client stopped dosing participants in its phase III and open-label extension trials in Huntington’s disease.